<code id='60DD5C1AE3'></code><style id='60DD5C1AE3'></style>
    • <acronym id='60DD5C1AE3'></acronym>
      <center id='60DD5C1AE3'><center id='60DD5C1AE3'><tfoot id='60DD5C1AE3'></tfoot></center><abbr id='60DD5C1AE3'><dir id='60DD5C1AE3'><tfoot id='60DD5C1AE3'></tfoot><noframes id='60DD5C1AE3'>

    • <optgroup id='60DD5C1AE3'><strike id='60DD5C1AE3'><sup id='60DD5C1AE3'></sup></strike><code id='60DD5C1AE3'></code></optgroup>
        1. <b id='60DD5C1AE3'><label id='60DD5C1AE3'><select id='60DD5C1AE3'><dt id='60DD5C1AE3'><span id='60DD5C1AE3'></span></dt></select></label></b><u id='60DD5C1AE3'></u>
          <i id='60DD5C1AE3'><strike id='60DD5C1AE3'><tt id='60DD5C1AE3'><pre id='60DD5C1AE3'></pre></tt></strike></i>

          entertainment

          entertainment

          author:focus    Page View:9519
          Eli Lilly headquarters
          Kristoffer Tripplaar/AP

          Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

          It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

          advertisement

          At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more
          Obesity now affects over 1 billion people worldwide, study finds
          Obesity now affects over 1 billion people worldwide, study finds

          AdobeMorethan1billionpeople—oroneineightpeopleworldwide—arenowestimatedtohaveobesity,anewstudyfinds.

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Why getting cancer drugs just got harder for rural patients

          AdobeIrecentlystartedapatientwithmetastatictriple-positivebreastcancerpatientonatargetedtherapyregim